Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called ABX464, which contains the active substance obefazimod. The study is aimed at individuals with ulcerative colitis, a condition that causes inflammation and sores in the colon and rectum. The trial will evaluate the effectiveness and safety of taking ABX464 once daily in capsule form. Participants will be randomly assigned to receive either the medication or a placebo, which looks like the medication but does not contain the active substance.

The purpose of the study is to compare how well obefazimod works against a placebo in improving the condition of the colon as seen through an endoscope, a tool used to look inside the body, and in reducing symptoms. The study will last for a period of eight weeks, during which participants will take the medication or placebo daily. The trial will monitor the participants' health and any changes in their symptoms throughout this period.

Participants will be assessed for improvements in their condition, such as reduced inflammation and fewer symptoms, by the end of the study. The trial will also keep track of any side effects or adverse events that may occur. This research aims to provide more information on the potential benefits and risks of using ABX464 for treating ulcerative colitis.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to sign a written informed consent form. This document confirms your understanding and agreement to participate in the trial.

    You must meet specific criteria, such as being at least 16 years old (or 18 in certain regions) and having a documented diagnosis of moderately to severely active ulcerative colitis.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility. This includes reviewing your medical history and conducting necessary tests, such as endoscopy and biopsies, to confirm your condition.

  3. Step 3

    Treatment assignment

    You will be randomly assigned to receive either the investigational medication ABX464 or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drug.

    The medication is administered in the form of a hard capsule taken orally once daily.

  4. Step 4

    Treatment period

    The treatment period lasts for 8 weeks. During this time, you will take the assigned capsule daily as instructed.

    You will be monitored for any changes in your condition and any side effects you may experience.

  5. Step 5

    Follow-up visits

    Regular follow-up visits will be scheduled to assess your progress. These visits will include evaluations of your symptoms and overall health.

    The primary goal is to determine the proportion of participants who achieve endoscopic improvement and symptomatic remission by the end of the 8-week period.

  6. Step 6

    Final assessment

    At the end of the 8-week treatment period, a final assessment will be conducted. This will include a review of your response to the treatment and any side effects experienced.

    The study aims to evaluate the safety and effectiveness of the medication compared to the placebo.

Who can join the trial?

9 criteria

  • Must be a male or female who is at least 16 years old. In some countries, you must be at least 18 years old.
  • If you are a teenager, you must weigh at least 40 kg (about 88 pounds) and have reached full physical development (known as Tanner Stage 5).
  • You need to understand, sign, and date a written consent form before any study procedures. If you are underage, your country's consent rules must be followed.
  • Must have a documented diagnosis of ulcerative colitis, confirmed by a procedure called endoscopy and tissue examination (histology).
  • Must have active disease, shown by a specific score (called the modified Mayo score) of 5 or more, with certain subscores for symptoms like rectal bleeding and endoscopy results.
  • Must have tried and not responded well to at least one of the following treatments: corticosteroids, immunosuppressants, biologic or biosimilar therapies, S1P receptor modulators, JAK inhibitors, or new drugs approved during the study. Not responding to only 5-ASA or sulfasalazine is not enough.
  • Women who can have children and men with partners who can have children must agree to follow birth control requirements.
  • Must be able and willing to attend study visits and follow study procedures.
  • Must have health insurance if required by the country or state where the study is conducted.

Who cannot join the trial?

10 criteria

  • Patients with any other significant health condition that might interfere with the study.
  • Patients who have had a recent surgery related to the digestive system.
  • Patients who are currently using other medications that might affect the study results.
  • Patients with a history of severe allergic reactions.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial recently.
  • Patients with a history of substance abuse.
  • Patients who have been diagnosed with cancer in the past five years.
  • Patients with active infections that require treatment.
  • Patients with a history of heart disease or stroke.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Obefazimod is a medication being studied for its potential to help people with ulcerative colitis, a condition that causes inflammation and sores in the colon. This medication is taken once a day and is being tested to see if it can improve the appearance of the colon when viewed through a camera (endoscopic improvement) and help reduce the symptoms of the disease, such as diarrhea and abdominal pain, leading to a state where the symptoms are minimal or gone (symptomatic remission). The goal of the trial is to determine if obefazimod is more effective than a placebo, which is a substance with no active medication, in achieving these improvements.

What is already known about the treatment

Obefazimod – Obefazimod is administered orally in the form of a once-daily pill. It is currently being studied in clinical trials for its effectiveness and safety in treating moderately to severely active ulcerative colitis, a condition that causes inflammation and sores in the digestive tract. The medication works by targeting specific molecules in the body to reduce inflammation and improve symptoms. It is classified as an anti-inflammatory agent, and its development is focused on providing relief for individuals with ulcerative colitis.

Investigated diseases

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory condition affecting the colon and rectum. It is characterized by continuous inflammation of the innermost lining of the large intestine, leading to the formation of ulcers. The disease typically begins in the rectum and may extend to involve the entire colon. Symptoms often include abdominal pain, diarrhea, and rectal bleeding. The inflammation can cause frequent and urgent bowel movements, often with mucus or pus. Over time, the disease can lead to complications such as colon narrowing or increased risk of colon cancer.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-500536-11-01Protocol codeABX464-106Estimated enrolment702 patientsSponsorAbivax

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).